Ryan Kiser, MD
Neurology · Seattle, WANPI 1912439670
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $747 of the $954 with a category attached, or 78.3%. It is spread thinly across 16 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $375 and has fallen 93.8% since, to $23 in 2022.
Across 51 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acorda Therapeutics, Inc$194
- Supernus Pharmaceuticals, Inc.$126
- Eisai Inc.$113
- AstraZeneca$85
- Amgen$76
- SK Life Science, Inc.$70
- plus $291 from 10 others
What the payments were for
- Speaking & faculty fees$19420%
- Food & beverage$74778%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acorda Therapeutics, Inc | 11 | $194 |
| Supernus Pharmaceuticals, Inc. | 6 | $126 |
| Eisai Inc. | 6 | $113 |
| AstraZeneca | 4 | $85 |
| Amgen(2 entities) | 4 | $76 |
| SK Life Science, Inc. | 3 | $70 |
| AbbVie(2 entities) | 3 | $49 |
| Lundbeck LLC | 2 | $42 |
| Adamas Pharmaceuticals, Inc. | 2 | $38 |
| Greenwich Biosciences, Inc. | 2 | $31 |
| Biogen | 2 | $31 |
| Lilly USA, LLC | 2 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| EMD Serono, Inc. | 1 | $17 |
How this compares
$954 in reported general payments places this provider in the 65th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Seattle
- Pavle RepovicSeattle$1.1M
- Nathaniel WatsonSeattle$486K
- Christyn EdmundsonSeattle$318K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
- Michael RosenbloomSeattle$179K
- Michael WeissSeattle$103K
- Sylvia LucasSeattle$90K
- Shuvro RoySeattle$46K
- Lucas McCarthySeattle$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.